A new simple chronic heart failure prognostic index based on five general parameters

Helena Hipólito-Reis1, Carolina Guimarães1, Catarina Elias1

  • 1Internal Medicine Department, Centro Hospitalar e Universitário São João, Portugal.

PubMed

Insights

A new index combining B-type natriuretic peptide (BNP) with age, sodium, hemoglobin, and kidney function improves heart failure (HF) mortality prediction. Patients with a high BASIC index score face nearly triple the risk of death.

Area of Science:

  • Cardiology
  • Clinical Medicine
  • Biomarker Research

Background:

  • Prognostic prediction in heart failure (HF) is complex, with no single marker proving consistently effective.
  • Existing methods often lack comprehensive predictive power for patient outcomes.

Purpose of the Study:

  • To develop and validate a novel prognostic index for heart failure (HF) using readily available clinical parameters.
  • To assess if this new index, the BASIC index, improves risk stratification compared to B-type natriuretic peptide (BNP) alone.

Main Methods:

  • Retrospective analysis of 1065 adult outpatients with chronic systolic dysfunction heart failure.
  • Calculation of the BASIC index: (BNP * age^2) / (serum sodium * hemoglobin * eGFR).
  • Evaluation of the index's association with all-cause mortality using receiver operator characteristic (ROC) curves and Cox regression analysis.

Main Results:

  • The BASIC index demonstrated superior prognostic performance (AUC 0.73) compared to BNP alone (AUC 0.69) in predicting all-cause mortality.
  • A BASIC index cut-off of 9.3 identified patients with significantly higher mortality risk.
  • Patients with a BASIC index > 9.3 had a multivariate-adjusted hazard ratio of 2.70 for all-cause mortality.

Conclusions:

  • The BASIC index, incorporating BNP, age, serum sodium, hemoglobin, and estimated glomerular filtration rate (eGFR), significantly enhances prognostic prediction in heart failure.
  • A BASIC index above 9.3 identifies patients with a nearly 3-fold increased risk of death, offering a valuable tool for risk stratification.
Abstract

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.3K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
311
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
507
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
375